308 related articles for article (PubMed ID: 23955073)
21. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A
Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332
[TBL] [Abstract][Full Text] [Related]
22. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
[TBL] [Abstract][Full Text] [Related]
23. ABT-737 synergizes with bortezomib to induce apoptosis, mediated by Bid cleavage, Bax activation, and mitochondrial dysfunction in an Akt-dependent context in malignant human glioma cell lines.
Premkumar DR; Jane EP; DiDomenico JD; Vukmer NA; Agostino NR; Pollack IF
J Pharmacol Exp Ther; 2012 Jun; 341(3):859-72. PubMed ID: 22393246
[TBL] [Abstract][Full Text] [Related]
24. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.
van Delft MF; Wei AH; Mason KD; Vandenberg CJ; Chen L; Czabotar PE; Willis SN; Scott CL; Day CL; Cory S; Adams JM; Roberts AW; Huang DC
Cancer Cell; 2006 Nov; 10(5):389-99. PubMed ID: 17097561
[TBL] [Abstract][Full Text] [Related]
25. Actinomycin D synergistically enhances the efficacy of the BH3 mimetic ABT-737 by downregulating Mcl-1 expression.
Olberding KE; Wang X; Zhu Y; Pan J; Rai SN; Li C
Cancer Biol Ther; 2010 Nov; 10(9):918-29. PubMed ID: 20818182
[TBL] [Abstract][Full Text] [Related]
26. γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells.
Séveno C; Loussouarn D; Bréchet S; Campone M; Juin P; Barillé-Nion S
Breast Cancer Res; 2012 Jun; 14(3):R96. PubMed ID: 22703841
[TBL] [Abstract][Full Text] [Related]
27. Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations.
Larrue C; Saland E; Vergez F; Serhan N; Delabesse E; Mansat-De Mas V; Hospital MA; Tamburini J; Manenti S; Sarry JE; Récher C
Mol Cancer Ther; 2015 Oct; 14(10):2364-73. PubMed ID: 26206337
[TBL] [Abstract][Full Text] [Related]
28. Ionizing radiation sensitizes breast cancer cells to Bcl-2 inhibitor, ABT-737, through regulating Mcl-1.
Wu H; Schiff DS; Lin Y; Neboori HJ; Goyal S; Feng Z; Haffty BG
Radiat Res; 2014 Dec; 182(6):618-25. PubMed ID: 25409124
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).
Konopleva M; Watt J; Contractor R; Tsao T; Harris D; Estrov Z; Bornmann W; Kantarjian H; Viallet J; Samudio I; Andreeff M
Cancer Res; 2008 May; 68(9):3413-20. PubMed ID: 18451169
[TBL] [Abstract][Full Text] [Related]
30. Dihydroartemisinin Enhances the Therapeutic Efficacy of BH3 Mimetic Inhibitor in Acute Lymphoblastic Leukemia Cells via Inhibition of Mcl-1.
Nazmabadi R; Pooladi M; Amri J; Abbasi Y; Karami H; Darvish M
Asian Pac J Cancer Prev; 2024 Jan; 25(1):325-332. PubMed ID: 38285800
[TBL] [Abstract][Full Text] [Related]
31. Hypoxic human cancer cells are sensitized to BH-3 mimetic–induced apoptosis via downregulation of the Bcl-2 protein Mcl-1.
Harrison LR; Micha D; Brandenburg M; Simpson KL; Morrow CJ; Denneny O; Hodgkinson C; Yunus Z; Dempsey C; Roberts D; Blackhall F; Makin G; Dive C
J Clin Invest; 2011 Mar; 121(3):1075-87. PubMed ID: 21393866
[TBL] [Abstract][Full Text] [Related]
32. YM155 enhances ABT-737-mediated apoptosis through Mcl-1 downregulation in Mcl-1-overexpressed cancer cells.
Woo SM; Min KJ; Seo BR; Seo YH; Jeong YJ; Kwon TK
Mol Cell Biochem; 2017 May; 429(1-2):91-102. PubMed ID: 28120212
[TBL] [Abstract][Full Text] [Related]
33. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis.
Miller LA; Goldstein NB; Johannes WU; Walton CH; Fujita M; Norris DA; Shellman YG
J Invest Dermatol; 2009 Apr; 129(4):964-71. PubMed ID: 18987671
[TBL] [Abstract][Full Text] [Related]
34. Norcantharidin enhances ABT-737-induced apoptosis in hepatocellular carcinoma cells by transcriptional repression of Mcl-1.
Zhang S; Li G; Ma X; Wang Y; Liu G; Feng L; Zhao Y; Zhang G; Wu Y; Ye X; Qin B; Lu J
Cell Signal; 2012 Sep; 24(9):1803-9. PubMed ID: 22609455
[TBL] [Abstract][Full Text] [Related]
35. ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation.
Russo M; Spagnuolo C; Volpe S; Tedesco I; Bilotto S; Russo GL
Biochem Pharmacol; 2013 Apr; 85(7):927-36. PubMed ID: 23353698
[TBL] [Abstract][Full Text] [Related]
36. Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells.
Mazumder S; Choudhary GS; Al-Harbi S; Almasan A
Cancer Res; 2012 Jun; 72(12):3069-79. PubMed ID: 22525702
[TBL] [Abstract][Full Text] [Related]
37. ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents.
Touzeau C; Dousset C; Bodet L; Gomez-Bougie P; Bonnaud S; Moreau A; Moreau P; Pellat-Deceunynck C; Amiot M; Le Gouill S
Clin Cancer Res; 2011 Sep; 17(18):5973-81. PubMed ID: 21821698
[TBL] [Abstract][Full Text] [Related]
38. Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML.
Vachhani P; Bose P; Rahmani M; Grant S
Physiol Genomics; 2014 Jul; 46(13):448-56. PubMed ID: 24824212
[TBL] [Abstract][Full Text] [Related]
39. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of NANOG/NANOGP8 downregulates MCL-1 in colorectal cancer cells and enhances the therapeutic efficacy of BH3 mimetics.
Mattoo AR; Zhang J; Espinoza LA; Jessup JM
Clin Cancer Res; 2014 Nov; 20(21):5446-55. PubMed ID: 25208882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
